Key Figures at a Glance Eli Lilly Q1 2026: total revenue $19.8B (+56% YoY), adjusted EPS $8.55 (+156%), full-year guidance raised to $82-85B Mounjaro + Zepbound combined Q1 revenue: $12.8B, with Mounjaro at $8.66B and Zepbound at $4.16B Foundayo (orforglipron): FDA approved April 1, 2026
Really interesting take Andy Lee if a mechanism can create multiple blockbusters, what do you think becomes the bigger moat over time: first-mover advantage, best-in-class efficacy, or the ability to expand the category itself
PMID: 233 UllahH
Each order of GLP-1 Microdose includes three 1mL vials of GLP-1 and, if clinically appropriate, an additive (B-12, Glycine, or L-Carnitine)
These evidences are crucial for optimizing current therapeutic strategies for preterm infants and ultimately enhancing their quality of life